文献速递淋巴瘤

高级别B细胞淋巴瘤非特指型:中枢神经系统受累及多中心系列结局

High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series.
PubMed 文献 · Blood Adv · 2024-01-01

这项多中心回顾性研究纳入2016至2021年美国20家机构治疗的160例新诊断高级别B细胞淋巴瘤非特指型(HGBL NOS)成人患者,7%在诊断时即有中枢神经系统(CNS)受累,3年CNS复发累积发生率为11%;基线CNS受累与MYC重排及睾丸或女性盆腔受累相关,复发后预后差。

要点

  • 160例HGBL NOS中11例(7%)诊断时即有CNS受累,3年CNS复发累积发生率为11%。
  • 基线CNS受累与MYC重排(OR=3.5)及睾丸(男性)或女性盆腔受累(OR=8.1)相关。
  • 伴与不伴基线CNS受累者中位PFS分别为4年与2.4年,无显著差异(P=0.45)。

核心结论

  • HGBL NOS诊断时CNS受累率为7%,3年CNS复发累积发生率为11%,基线CNS受累者复发风险最高(48.5% vs 8%)。
  • CNS复发与血液或骨髓受累、CD5表达、非生发中心B细胞亚型及「双表达淋巴瘤」表型显著相关,而高CNS IPI不相关。
  • 复发HGBL NOS预后差,无论复发为系统性还是局限于CNS,几乎所有CNS复发患者最终死于该病。

研究设计与样本

  • 多中心回顾性研究,纳入2016至2021年美国20家机构治疗的160例新诊断HGBL NOS成人患者。

主要发现

  • 11例(7%)诊断时存在基线CNS受累:软脑膜6例、脑实质4例、两者兼有1例。
  • 基线CNS受累仅与MYC重排(OR=3.5)及睾丸(男性)或女性盆腔(女性)受累(OR=8.1)显著相关。
  • 伴与不伴基线CNS受累者中位PFS分别为4年与2.4年,生存结局无显著差异(P=0.45)。
  • 3年CNS复发累积发生率为11%;基线CNS受累者CNS复发风险最高(48.5% vs 不伴基线CNS受累者8%),并被排除于CNS复发危险因素分析之外。
  • CNS复发风险与血液或骨髓受累、CD5表达、非生发中心B细胞亚型及「双表达淋巴瘤」表型显著相关,高CNS IPI则不相关。

临床怎么用

  • 作者描述了HGBL NOS的基线CNS受累率、CNS复发风险及管理策略,原文未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Little is known about the central nervous system (CNS) risk in high-grade B-cell lymphoma, not otherwise specified (HGBL NOS). Hence, we sought to describe the rates of baseline CNS involvement, risk of CNS recurrence after primary therapy, and management strategies in HGBL NOS. In this multicenter retrospective study, we included 160 adults with newly diagnosed HGBL NOS treated between 2016 and 2021 at 20 US institutions. Eleven patients (7%) had baseline CNS involvement at diagnosis (leptomeningeal = 6, parenchymal = 4, and both = 1). Baseline CNS involvement was significantly associated only with MYC rearrangement (OR = 3.5) and testicular (in men) or female pelvic (in women) involvement (OR = 8.1). There was no significant difference in survival outcomes between patients with HGBL NOS with (median PFS = 4 years) or without (median PFS = 2.4 years) baseline CNS involvement (P = 0.45). The cumulative incidence of CNS recurrence at 3 years was 11%. Patients with baseline CNS involvement were at the highest risk (48.5% vs 8% for those without baseline CNS involvement) and were excluded from the risk factors analysis for CNS recurrence. The risk for CNS recurrence was significantly associated with blood or bone marrow involvement, CD5 expression, non-germinal center B-cell subtype, and "dual-expresser lymphoma" phenotype, however, high CNS IPI was not. The prognosis of relapsed HGBL NOS was poor, regardless of whether recurrence was systemic or limited to the CNS, and with currently available salvage strategies, including autologous transplantation and chimeric antigen receptor T-cell modalities, almost all patients with CNS recurrence ultimately succumbed to their disease.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Epperla N, Zayac AS, Landsburg DJ, et al. High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series. Blood Adv. 2024. PMID: 39189932. doi:10.1182/bloodadvances.2024013791

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。